Carlos Jimenez Naranjo is a PhD candidate at Molecular Horizons, University of Wollongong. His research interest is focused on the use of cannabinoids to improve cognitive deficits in neuropsychiatric disorders, which are untreatable with current medications. Carlos is experienced in molecular analysis techniques in both cellular and animal models as well as in adeno-associated viral (AAV) vectors design and production for gene therapy purposes.
Carlos’ qualifications include a Bachelor’s in Biotechnology at the University of Leon (Spain) and a Master of Science (MSc) in Gene Therapy at Imperial College London (UK). During his undergraduate program, Carlos worked in collaboration with Dr Katrina Green at the Illawarra Health and Medical Research Institute (IHMRI) to explore the effect of cannabidiol on the muscarinic system in a schizophrenia rat model as part of an international student exchange program at the University of Wollongong. His postgraduate master thesis focused on analysing the molecular changes in the brain of an epilepsy mouse model following AAV-mediated CDKL5 gene augmentation therapy.
Carlos’ PhD project aims to develop a unique formulation of cannabinoids and other cannabis-derived chemicals that can target high levels of inflammation and oxidative stress as a novel therapy for cognitive impairments in schizophrenia. The results of this research will help to develop more effective treatment options for schizophrenia patients, particularly those with an increased neuro-inflammatory state, which present worsening of symptoms.